Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy

Area of Science:

• Immunology
• Biomaterials Science
• Cancer Therapy

Background:

• Dendritic cell (DC) vaccines are under development for cancer and infectious diseases.
• Current DC vaccine delivery methods aim to trigger immune responses.
• Challenges include maintaining DC viability and creating an inflammatory environment at the injection site.

Purpose of the Study:

• To develop an injectable hydrogel matrix for sustained delivery of dendritic cells (DCs).
• To create a localized inflammatory milieu by trapping DC-secreted factors.
• To evaluate the in vivo immune cell recruitment and T cell activation capabilities of the DC-loaded hydrogel system.

Main Methods:

• Development of a self-gelling alginate formulation by mixing calcium-loaded alginate microspheres, soluble alginate, and DCs.
• Subcutaneous injection of the alginate/DC formulation ('vaccination nodes') into mice.
• Assessment of host DC and T cell recruitment to the injection site using adoptive transfer models and tracking of antigen-specific T cells.

Main Results:

• The alginate formulation rapidly gelled in vivo, forming 'vaccination nodes'.
• Injected nodes attracted host DCs and a significant number of T cells to the site over one week.
• Activated antigen-specific T cells were recruited to the alginate matrix in a DC-dependent manner.
• Some inoculated DCs migrated to draining lymph nodes.

Conclusions:

• Injectable alginate hydrogels can effectively harbor DCs and promote localized immune cell accumulation.
• This DC/alginate hydrogel system shows potential for immunotherapy by directing immune cell and factor delivery.
• The approach may be valuable for enhancing immunotherapies at tumor or infection sites.